A protein-based companion diagnostic to detect patients with
disease driven by dysregulation of the complement pathway

A protein-based companion diagnostic to detect patients with disease driven by dysregulation of the complement pathway

In addition to CTx001, CTx002 and CTx003, we are also developing a platform to quantify precisely proteins involved in regulation of the complement cascade. This will allow us to stratify patients with AMD and other conditions so that they receive the right treatment.

Our unique technology allows us to identify and quantify all relevant components in a single, multiplexed assay. This enables patient stratification in complex disease such as AMD, and to allow therapeutic monitoring for complement-based interventions in systemic disease.

Biomarkers developed by Complement Therapeutics

FH, FHL-1, FHR1-5

Proteins encoded at the RCA locus whose expression likely underpins Chr1-related GA – will help support the selection of patients for efficacious CTx treatments.

C3b breakdown products

Directly demonstrates balance of circulating complement pathway – will provide a direct read-out of FH-related level of complement activation. Can be used as diagnostics or proxy for efficacy for all therapeutic programmes.

Factor I

A small percentage of patients with geographic atrophy have mutations in the CFI gene resulting in low levels of FI. This is the 3rd protein involved in this key complement regulatory step. This assay can rule out patients for CTx treatments. Along the other Dx programmes, this platform offers a complete picture of complement in disease.

Presently the Complementome methods have been validated in normal human samples and two distinct disease cohorts.

Once fully developed this platform will allow the measurement of all fluid-phase complement proteins.

Complementome methods validated in normal human samples and two distinct disease cohorts.

Core Technology Facility
46 Grafton Street
Manchester
M13 9NT
United Kingdom


Created by HTP Digital